An observational study in Critical Illness and Muscle Atrophy, sponsored by Frank Vandenabeele. Recruiting at 1 site in Belgium. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2024-01-31.
Sponsored by Frank Vandenabeele · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies in Muscular Atrophy with a site in Belgium — 2 open to participants now, 4 under way, 2 of them phase 3. Muscular Atrophy · Belgium.
Among the 19 studies in Muscular Atrophy with a site in Belgium, this one is one of 4 that started in 2023, is one of 4 observational ones, and was the 18th registered.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
Browse Muscular Atrophy studies →2 of the 19 studies in Muscular Atrophy with a site in Belgium are open now. Recruiting first, the newest first:
Dr F Duprez · Sites in Belgium
Ages 18+
A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →
Of the 51 Muscular Atrophy studies recruiting now, 25 (49%) set no upper age limit and 13 (25%) stop at 75 or younger; 4 take children under 18; 16 take healthy volunteers.
This study: 18 Years to 90 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 6 · Phase 3 7
First in 2003; this study’s year is marked. 4 started in 2023.
This study's planned enrollment of 20 is below the median of 61 across 73 observational studies indexed under Muscular Atrophy.
Median enrollment 160 across the 15 interventional studies, 30 across the 4 observational. Of the 13 that completed or were terminated, 8 (62%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 19 have an industry lead sponsor. The 10 most frequent:
This is the only study on the registry with Frank Vandenabeele as lead sponsor.
Frank Vandenabeele has 1 study filed under Muscular Atrophy — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 19 studies in Muscular Atrophy with a site in Belgium, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Muscle wasting occurs rapidly in critically ill patients and impacts both short and long term outcomes. Altered protein metabolism drives muscle loss in ICU patients, with muscle protein breakdown exceeding muscle protein synthesis (MPS). Interventions aimed at attenuating muscle loss by stimulating MPS rates are hampered by a lack of knowledge on altered muscle protein turnover rates during critical illness. Only a few studies have specifically assessed muscle protein synthesis by using contemporary intravenous stable isotope infusions, which allows the assessment of MPS over a short (\<9 hours) period of time. Results from such acute studies can be difficult to extend or translate into long-term clinical practice and outcomes. Oral deuterated water (2H2O) dosing provides an alternative method that can be utilized to extend the measurement of muscle protein synthesis over a period of several days or weeks. It could therefore provide a valuable tool to study muscle protein synthesis during ICU admission and the impact of different anabolic interventions. Although multiple studies using the deuterated water methodology have been performed in both healthy volunteers and patients, it has not yet been performed in critically ill patients.
In this prospective study the investigators aim to assess fractional rates of muscle protein synthesis over a period of (maximal) 7 days in critically ill patients admitted to the intensive care unit. Secondly, the investigators aim to assess mechanisms of acute muscle wasting on an microscopic, ultrastructural and molecular level. Furthermore, the investigators aim to investigate to what extent muscle fibre size is recovered 3 months after ICU discharge.
413 studies on the registry are indexed under Muscular Atrophy; 76 are open to participants now.
This study's planned enrollment of 20 is below the median of 61 across 73 observational studies indexed under Muscular Atrophy.
Browse Muscular Atrophy studies →This is the only study on the registry with Frank Vandenabeele as lead sponsor.
Compared within Muscular Atrophy, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Critical Illness. The counts are of registry records indexed under each term, refreshed daily. How we classify →
In total 20 patients admitted to the ICU will be included.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
muscle protein synthesis rate (%/h)
obtained by using deuterated water, muscle biopsy sampling and blood sampling
Time frame: 7 days of stay at the intensive care unit
skeletal muscle fiber characteristics 1
cross sectional area of muscle fibers
Time frame: 7 days of stay at the intensive care unit
skeletal muscle fiber characteristics 2
amount and distribution of muscle fibers (distribution will be calculated as: amount of type X / total amount of fibres)
Time frame: 7 days of stay at the intensive care unit
mRNA expression in skeletal muscle tissue 1
mRNA expression in skeletal muscle tissue of MAFBx (atrophy marker)
Time frame: 7 days of stay at the intensive care unit
mRNA expression in skeletal muscle tissue 2
mRNA expression in skeletal muscle tissue of MurF1 (atrophy marker)
Time frame: 7 days of stay at the intensive care unit
mRNA expression in skeletal muscle tissue 3
mRNA expression in skeletal muscle tissue of FOXO (atrophy marker)
Time frame: 7 days of stay at the intensive care unit
patient characteristic- age
age in years
Time frame: 7 days of stay at the intensive care unit
patient characteristic- body weight
body weight in kg
Time frame: 7 days of stay at the intensive care unit
patient characteristic- height
height in m
Time frame: 7 days of stay at the intensive care unit
patient characteristic- sex
male or female
Time frame: 7 days of stay at the intensive care unit
patient characteristics (medical1)
mechanical ventilation (duration in days)
Time frame: 7 days of stay at the intensive care unit
patient characteristics (medical2)
comorbidities (list of comorbidities)
Time frame: 7 days of stay at the intensive care unit
patient characteristics (medical3)
reason hospital admission
Time frame: 7 days of stay at the intensive care unit
patient characteristic- APACHE score II
APACHE II score = acute physiology score + age points + chronic health points. Minimum score = 0; maximum score = 71.
Time frame: 7 days of stay at the intensive care unit
patient characteristic- food intake
food intake (energy in kcal and protein intake in g/kg/d)
Time frame: 7 days of stay at the intensive care unit
patient characteristic- LOS
Length of stay ICU and hospital (in days)
Time frame: Stay at the intensive care unit and Hospital (up to 1 year)
muscle volume
3d ultrasound assessed at follow up visit
Time frame: 3 months post-hospital discharge
habitual food
Assessed using questionnaires at follow up visit (higher score means better intake)
Time frame: 3 months post-hospital discharge
habitual activity
Assessed using questionnaires at follow up visit (higher score means better intake)
Time frame: 3 months post-hospital discharge
muscle hand grip strength
hand grip strength using the JAMAR dynamometer in kg
Time frame: 3 months post-hospital discharge
leg muscle strength
1RM upper leg at follow up visit
Time frame: 3 months post-hospital discharge
Functional capacity 1
SPPB at follow up visit (short physical performance battery)
Time frame: 3 months post-hospital discharge
Functional capacity 2
6min walking test at follow up visit
Time frame: 3 months post-hospital discharge
Quality of life questionnaire
SF-36 at follow up visit (Short Form Health Survey 36 items) range score between 0-100, lower score represents great health related problems
Time frame: 3 months post-hospital discharge
Quality of life questionnaires
Euro-QoL-5D-5-level at follow up visit (Euro quality of life 5 Dimension 5 level) Answers can be converted into EQ-5D index, an utility scores anchored at 0 for death and 1 for perfect health
Time frame: 3 months post-hospital discharge
Started Apr 2023 (actual). Primary completion is estimated for Apr 2025, 24 months after the start.
Of 36 non-industry observational studies under Muscular Atrophy, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 66. This study's planned 24 months is below that.
Counting every sponsor, half of 38 studies reached it within 35 months; a quarter within 18 and three quarters within 66.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.